Systemic Inflammation in Older Adults With Asthma–COPD Overlap Syndrome

Juan-juan Fu,1,2,4 Vanessa M. McDonald,2,3,4 Peter G. Gibson,2,4,5 Jodie L. Simpson2,4*

1Respiratory Group, Department of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu, China
2Priority Research Centre for Asthma and Respiratory Diseases, University of Newcastle; Hunter Medical Research Institute, Newcastle, NSW, Australia
3School of Nursing and Midwifery, Faculty of Health, University of Newcastle, NSW, Australia
4Department of Respiratory and Sleep Medicine, John Hunter Hospital, New Lambton, NSW, Australia
5Woolcock Institute of Medical Research, Sydney NSW, Australia

INTRODUCTION

With ageing, there is an increasing overlap of asthma and chronic obstructive pulmonary disease (COPD), such that many older patients with obstructive airway disease (OAD) have features of both asthma and COPD, termed asthma-COPD overlap syndrome.1 Hardin et al. reports that outcomes including health-related quality of life (HRQoL) impairment are worse for people with asthma-COPD overlap syndrome than those with COPD alone, and that these patients were more likely to experience frequent and severe exacerbations compared with COPD patients.2

Systemic inflammation is a feature of chronic inflammatory airway disease. While it is typically associated with COPD and ageing,3 systemic inflammation has recently been linked to some forms of asthma.4 In COPD, systemic inflammation with chronic low-grade elevation of circulating pro-inflammatory mediators such as C-reactive protein (CRP) and interleukin 6 (IL-6) is associated with accelerated disease progression, characterized by acute exacerbations,5 COPD-related hospitalization,6 and rapid decline of force expiratory volume in 1 second (FEV1).7 These same markers of systemic inflammation are also associated with ageing and comorbid diseases, such as cardiovascular disease (CVD),7 obesity,8 diabetes,8 and are believed to actively participate in the pathogenesis of these conditions.

Given that the prevalence of asthma-COPD overlap syndrome...
Systemic Inflammation in Asthma-COPD Overlap increases with age, it is unclear whether systemic inflammation is also a feature of this condition, and if so, which markers are involved in and what are the clinical correlates of these markers. The impact of the confounding effects of age, CVD and obesity on systemic inflammation in asthma-COPD overlap syndrome is also unknown. Systemic inflammation may also be a contributing factor to the increased morbidity (decreased quality of life, increased admission and greater decline in lung function) associated with the asthma-COPD overlap syndrome reported by Hardin et al.²

In this study we have therefore examined levels of systemic inflammatory mediators in asthma, COPD and asthma-COPD overlap syndrome, and identified potential clinical characteristics that were associated with levels of these markers. We have also examined clinical correlates and inflammatory markers that were associated with the asthma-COPD overlap syndrome, and tested the hypothesis that systemic inflammation is present in asthma-COPD overlap syndrome, and independently associated with clinical characteristics of obstructive airway disease.

**MATERIALS AND METHODS**

A cross-sectional study was conducted, involving 108 older people (>55 years of age) who underwent a multidimensional assessment of clinical and functional status and comorbidity.³ Baseline clinical characteristic data from this study are published elsewhere.³ Participants gave written informed consent. The Hunter New England Area Health Service and University of Newcastle Research Human Ethics Committees approved this study.

**Participants**

We recruited a total of 39 participants (age >55 years) without airways disease (healthy controls) by community advertisement. One hundred and eleven participants with obstructive airways disease were consecutively recruited according to physician diagnosis and spirometry from the Respiratory and Sleep Medicine Ambulatory Care Clinics at the John Hunter Hospital, Newcastle NSW, Australia. Patients that were excluded from the analysis if they were current smokers or had ceased within the previous 12 months, had other respiratory disease, and were participants who failed to have blood samples collected. Healthy controls were excluded if their spirometry was outside normal limits. After exclusions were applied, 79 patients with OAD and 29 healthy controls were included in this analysis (Fig. 1).

**Definitions of disease categories**

Diagnostic classification was performed using standardized objective criteria (Table 1).¹ Participants in the healthy group had no diagnosed airway disease, confirmed by a normal lung

---

Fig. 1. Participant recruitment flow chart.
Table 1. Physiological characteristics and definition of obstructive airway syndrome

| Healthy Control | Asthma | COPD | Asthma-COPD overlap syndrome |
|-----------------|-------|------|-----------------------------|
| Symptoms*       | –     | +    | +                           |
| Post bronchodilator FEV1/FVC% | ≥70 | ≥70 | <70 |
| Post bronchodilator FEV1% predicted | >80 | >80 | <80 |
| AHR or BDR      | –     | +    | +                           |

Table is reproduced from reference (1), by permission of the journal Thorax.

*At least one of the following respiratory symptoms: breathlessness, wheeze, cough, sputum production. Airway Hyperresponsiveness (AHR), FEV1 fall ≥15% from baseline after inhalation of 4.5% hypertonic saline. Bronchodilator responsiveness (BDR), post-bronchodilator FEV1 increased ≥200 mL and 12% compared with pre-bronchodilator FEV1.

function with post bronchodilator FEV1/FVC ≥70% and post-bronchodilator FEV1 >80% of predicted. Asthma was defined as episodic respiratory symptoms and reversible airflow obstruction with a post bronchodilator FEV1/FVC ≥70% and post-bronchodilator FEV1 >80% of predicted with airway hyper-responsiveness (AHR) or bronchodilator hyper-responsiveness (BHR). Participants with COPD had incompletely reversible airflow obstruction with a post bronchodilator FEV1/FVC <70% and post-bronchodilator FEV1 <80% of predicted and no AHR or bronchodilator responsiveness (BDR). Participants with the asthma-COPD overlap syndrome had respiratory symptoms, increased airflow variability (asthma, AHR or BDR) as well as incompletely reversible airflow obstruction (COPD, post-bronchodilator FEV1/FVC <70% and post-bronchodilator FEV1 <80% of predicted).

Study protocol

Participants attended three visits within one month to complete their assessments. Pre and post bronchodilator spirometry, symptoms, smoking status, medical history, and medication use were assessed at visit one and a sputum induction was undertaken. At visit 2, venepuncture with blood collection and a skin allergy test was performed, and sputum induction was repeated if sputum sample failed to be obtained in the first visit. On the final visit a hypertonic saline (4.5%) challenge was performed in those whose visit 1 FEV1 was >1.3 L as previously described.

Participant questionnaires

Questionnaires were completed which assessed respiratory symptoms such as cough, breathlessness, wheeze and mucus production. A smoking history was taken and smoking pack-years determined. Health status was measured using St George’s Respiratory Questionnaire (SGRQ). The Charlson Co-morbidity Index (CCI) was calculated using information collected in the medical history.

Pulmonary function tests

Participants withheld bronchodilators for their duration of action before testing. Three reproducible measurements of FEV1 and FVC were obtained (KoKo PD Instrumentation, Louisville, CO, USA) before and after inhalation of 400 mcg salbutamol via a metered dose inhaler with valved holding chamber (Volumatic, Allen and Hanbury’s, Melbourne Victoria, Australia). Predicted values were calculated according to Knudson et al.

Sputum induction and analysis

Sputum induction with hypertonic saline (4.5%) was performed as previously described. Airway inflammation was assessed using induced sputum. Lower respiratory sputum portions were selected from saliva, processed using dithiothreitol and differential cell counts obtained.

Measurement of systemic inflammatory mediators

Standard venepuncture and infection prevention standards were used during sample collection. Peripheral venous blood was collected into Vacutainer tubes (BD Worldwide, North Ryde, NSW, Australia). High sensitivity CRP (MP Biomedicals, Australasia, Seven Hills, NSW, Australia) and IL-6 (R&D Systems, Minneapolis, MN, USA) were determined in duplicate using enzyme-linked immunosorbent assay according to the manufacturers’ instructions. Elevated CRP and IL-6 levels were defined as CRP >4.12 mg/L and IL-6 >1.55 pg/mL based on prior data.

Statistical analysis

Data were analyzed using Stata 11 (Stata Corporation, College Station, Texas, USA). Results are reported as median and inter-quartile range (IQR) unless otherwise indicated. Analysis was performed using One-way ANOVA or Kruskal-Wallis test for more than 2 groups, as appropriate. Post-hoc analysis with Bonferroni adjustment was conducted for One-way ANOVA test, or using adjusted P<0.008 for Kruskal-Wallis test on statistically significant groups. The two-sample Wilcoxon Rank Sum test was used to test non-parametric data between 2 independent groups, and the Fishers’ exact test for categorical data. Independent predictors for asthma-COPD overlap syndrome were identified using univariate logistic regression followed by a multivariate logistic regression analysis. Variables that were tested in univariate logistic regression with P<0.1 were selected in multivariate logistic regression model. Demographic variables including age and sex were forced into multivariate regression analysis. Associations between systemic inflammatory mediators and clinical characteristics were determined using single and multiple linear regression. Levels of CRP and IL-6
were natural log transformed and reciprocal square roots transformed to normality, respectively. Results are reported as significant when \( P < 0.05 \).

**RESULTS**

**Clinical characteristics**

In 79 subjects with obstructive airways disease, there were 16 (20.3%) with asthma, 21 (26.6%) with COPD and 42 (53.2%) with asthma-COPD overlap syndrome (Table 2). The four groups had similar BMI (\( P = 0.316 \)), atopic status (\( P = 0.108 \)), inhaled corticosteroid use (\( P = 0.516 \)), history of cardiac dysfunction (\( P = 0.573 \)) and HMGCoA reductase inhibitor (statin) use (\( P = 0.169 \)). Most asthmatics in this study were never smokers, whereas 76.2% of participants in the COPD group (\( P = 0.006 \)) and 71.4% in the asthma-COPD overlap syndrome group (\( P = 0.005 \)) were ex-smokers.

Subjects with COPD and asthma-COPD overlap syndrome had significantly impaired lung function compared with healthy controls and the asthmatics, for both mean FEV1% predicted and FEV1/FVC ratio ranging from 50% to 55% (\( P < 0.001 \)). FEV1% predicted alone in asthma group was lower than that in healthy controls (\( P = 0.004 \)). The airway disease groups had higher CCI when compared with healthy controls (\( P < 0.001 \), but there was no difference within the disease groups (\( P = 0.130 \)) (Table 2).

Sputum eosinophil and neutrophil counts were different among the 4 groups as Table 2 shows, however no significant difference was found between any 2 groups comparison in the post-hoc analysis with the exception of a higher sputum eosinophil number in the asthma-COPD overlap syndrome group compared to healthy controls (\( P = 0.002 \)).

---

**Table 2. Participant characteristics by diagnostic group**

|                      | Healthy control | Asthma | COPD | Asthma-COPD overlap syndrome | \( P \) value |
|----------------------|-----------------|--------|------|-------------------------------|--------------|
| Number               | 29              | 16     | 21   | 42                            |              |
| Age, years, mean (SD)| 65.1 (6.9)      | 61.6 (7.5) | 69.9 (7.4) | 67.9 (7.3)                  | 0.270        |
| Range                | 55.4-80.8       | 56.0-83.0 | 57.6-82.0 | 55.8-87.3                     |              |
| Sex, M/F             | 15/14           | 6/10   | 8/13 | 21/21                         | 0.650        |
| BMI, mean (SD)       | 27.0 (3.7)      | 30.3 (6.4) | 27.9 (8.6) | 29.2 (6.7)                     | 0.316        |
| FEV1% pred, mean (SD)| 102.2 (17.3)    | 83.7 (8.1)* | 52.1 (14.0)* | 54.6 (19.5)*                          | \(< 0.001\) |
| FEV1/VC%, mean (SD)  | 77.1 (4.8)      | 73.8 (5.7) | 51.1 (12.6)* | 53.5 (11.8)*                     | \(< 0.001\) |
| Smokers: never/ex    | 13/16           | 11/5   | 5/16 | 12/30†                        | 0.016        |
| Smoking pack years, median (IQR) | 13 (2.1-36.3) | 3 (0.6-19) | 29 (14.1-44.0) | 34.8 (19.5-66.5)                      | 0.050        |
| Atopy, n (%)         | 9 (31.0)        | 7 (43.8) | 13 (61.9) | 23 (54.8)                     | 0.108        |
| AHR, n (%)           | N/A             | 12 (75.0) | 0 (0) | 38 (92.7)*†                   | \(< 0.001\) |
| ICS dose, BDP equivalent/d | N/A           | 1,000 (500-2,000) | 2,000 (1,000-2,000) | 2,000 (1,000-2,000)                      | 0.516        |
| HRQoL SGRQ, mean (SD)| N/A             | 40.8 (23.1) | 41.8 (18.2) | 41.8 (18.2)                     | 0.695        |
| Charlson comorbidity index (CCI), mean (SD) | 0.5 (1.1) | 3.1 (1.2)* | 3.8 (0.9)* | 3.8 (1.1)*†                   | \(< 0.001\) |
| Cardiac dysfunction, n (%) | 3 (10.3) | 3 (18.8) | 4 (19.1) | 10 (23.8)                     | 0.573        |
| Statin use, n (%)    | 3 (10.3)        | 6 (37.5) | 6 (28.6) | 9 (21.4)                       | 0.169        |
| Sputum eosinophils%, median (IQR) | 0.3 (0.3-8.0) | 3.5 (1.0-5.1) | 1.1 (0.3-3.0) | 1.3 (0.4-4.8)*                  | 0.012        |
| Sputum neutrophils%, median (IQR) | 41.8 (28.3-60.8) | 32.5 (13.5-52.3) | 65.6 (50.3-82.5) | 63.1 (43.9-84.4)                      | 0.006        |

\* \( P < 0.05 \) vs Healthy Control; † \( P < 0.05 \) vs Asthma; ‡ \( P < 0.05 \) vs COPD.

**Table 3. Levels of systemic inflammatory mediators in different groups**

| Systemic inflammatory markers | Health Control | Asthma | COPD | Asthma-COPD overlap syndrome | \( P \) value |
|------------------------------|----------------|--------|------|-------------------------------|--------------|
| CRP (mg/L), median (IQR)     | 2.2 (1.1-5.8) | 2.4 (1.0-5.5) | 6.7 (2.0-17.3) | 3.5 (1.7-8.5)                     | 0.020        |
| CRP > 4.12 mg/L, n (%)       | 11 (37.9)     | 4 (25.0) | 14 (66.7) | 20 (47.6)                       | 0.064        |
| IL-6 (pg/mL), median (IQR)   | 1.6 (1.1-2.6) | 1.4 (1.2-2.9) | 2.5 (1.5-4.9) | 2.9 (1.8-4.8)*†                 | 0.007        |
| IL-6 > 1.55 pg/mL, n (%)     | 16 (55.2)     | 6 (37.5) | 14 (66.7) | 34 (81.0)†                      | 0.010        |
| CRP > 4.12 mg/L, IL-6 > 1.55 pg/mL, n (%) | 10 (34.5) | 3 (18.8) | 11 (52.4) | 19 (45.2)                       | 0.157        |

\* \( P < 0.05 \) vs Healthy Controls; † \( P < 0.05 \) vs Asthma.
Levels of systemic inflammatory markers

There was evidence of systemic inflammation in asthma-COPD overlap syndrome groups (Table 3). CRP levels were different among the 4 groups ($P=0.020$). Median CRP level was higher in patients with COPD and asthma-COPD overlap syndrome but the difference was not significant compared with healthy controls and asthma groups. The proportion of subjects with an elevated CRP level was not different among the 4 groups ($P=0.064$).

IL-6 levels were highest in the asthma-COPD overlap syndrome group (Fig. 2), and were significantly elevated compared to healthy controls ($P=0.006$) and the asthma group ($P=0.0086$). Significantly more people with asthma-COPD overlap syndrome had increased IL-6 levels (81.0%) compared to asthma (37.5%, $P=0.001$). No difference was found in IL-6 level ($P=0.688$) or proportion of patients with elevated IL-6 ($P=0.209$) between COPD and asthma-COPD overlap syndrome groups (Table 3).

Multivariate analysis to detect independent predictors of asthma-COPD overlap syndrome

We performed multivariate logistic regression analysis to determine which clinical feature could be independently associated with asthma-COPD overlap syndrome (Table 4). In the univariate logistic regression analysis, FEV1% predicted, sputum neutrophil counts, CCI and IL-6 level significantly predicted the risk of having asthma-COPD overlap syndrome ($P<0.1$). FEV1% predicted was removed from the multivariate regression model due to the physiological classification of asthma-COPD overlap syndrome. In a multivariate regression model adjusting for confounders, the associations of age (adjusted OR=0.894, $P=0.012$) and 1/SQRT IL-6 level (adjusted OR=0.089, $P=0.036$) with a decreased likelihood of asthma-COPD overlap syndrome were identified. Co-morbidity measured by CCI (adjusted OR=2.223, $P=0.001$) was associated with an increased likelihood of having asthma-COPD overlap syndrome in the model independent of other variables.

Table 4. Logistic regression to identify risk factors for asthma-COPD overlap syndrome

| Variable                  | OR   | 95% CI       | Pvalue |
|---------------------------|------|--------------|--------|
| Age                       | 1.010| 0.958-1.065  | 0.708  |
| Sex                       | 0.784| 0.361-1.703  | 0.538  |
| BMI                       | 1.027| 0.967-1.090  | 0.389  |
| Smoking                   | 1.959| 0.857-4.482  | 0.111  |
| FEV1% predicted           | 0.953| 0.333-0.973  | <0.001 |
| Sputum neutrophils%       | 1.017| 1.000-1.035  | 0.052  |
| CCI                       | 1.846| 1.367-2.492  | <0.001 |
| Statin use                | 0.927| 0.364-2.363  | 0.874  |
| CVD                       | 1.750| 0.658-4.655  | 0.262  |
| LN CRP                    | 1.181| 0.837-1.666  | 0.343  |
| 1/SQRT IL-6               | 0.092| 0.017-0.494  | 0.005  |

Multiple Regression (Pseudo $R^2=0.254$, $P<0.001$)

| Variable                  | OR   | 95% CI       | Pvalue |
|---------------------------|------|--------------|--------|
| Age                       | 0.894| 0.819-0.976  | 0.012  |
| Sex                       | 1.345| 0.471-3.841  | 0.580  |
| CCI                       | 2.223| 1.369-3.612  | 0.001  |
| Sputum neutrophils%       | 1.005| 0.985-1.025  | 0.633  |
| 1/SQRT IL-6               | 0.089| 0.009-0.858  | 0.036  |

* $P=0.006$

* $P=0.0086$

Fig. 2. Systemic inflammatory mediators in different groups. *With statistical significance.
Systemic Inflammation in Asthma–COPD Overlap

**Fig. 3.** (A) Correlation between FEV1% predicted with IL-6, (B) Levels of IL-6 in patients with CVD vs non-CVD.

**Associations between systemic inflammation mediators and clinical characteristics**

In univariate regression, serum CRP level (LN CRP) was associated with BMI (Coef. = 0.059, 95% CI [0.027, 0.090], \( P < 0.001 \)), FEV1% predicted (Coef. = -0.012, 95% CI [-0.020, -0.005], \( P = 0.002 \)), sputum neutrophil counts (Coef. = 0.014, 95% CI [0.005, 0.023], \( P = 0.003 \)) and CCI (Coef. = 0.173, 95% CI [0.057, 0.289], \( P = 0.004 \)), however, when adjusted with age, sex, smoking history, statin use and CVD in a multivariate regression model (\( R^2 = 0.245 \), \( P = 0.004 \)), BMI was the only clinical characteristic that was associated with CRP level (Coef. = 0.052, 95% CI [0.016, 0.089], \( P = 0.005 \)).

IL-6 level was negatively associated with FEV1% predicted (calculated as \( 1/SQRT \) IL-6, Coef. = -0.004, 95% CI [0.002, 0.005], \( P < 0.001 \)), and was positively associated with age (Coef. = -0.011, 95% CI [-0.017, -0.004], \( P = 0.002 \)), sputum neutrophil percentage (Coef. = -0.003, 95% CI [-0.005, -0.001], \( P = 0.005 \)) and concurrence of CVD (Coef. = -0.227, 95% CI [-0.349, -0.104], \( P < 0.001 \)) in univariate regression. Correlation between IL-6 level and FEV1% predicted is shown in Fig. 3A. Subjects with CVD had higher IL-6 levels (4.1, 2.7-5.0) than those without CVD history (1.9, 1.2-3.4) (\( P < 0.001 \), Fig. 3B). After controlling for sex, BMI, smoking history, CCI and statin use in a linear regression model (\( R^2 = 0.436 \), \( P < 0.001 \)), age (Coef. = -0.012, 95% CI [-0.019, -0.004], \( P = 0.002 \)), FEV1% predicted (Coef. = 0.004, 95% CI [0.001, 0.006], \( P = 0.004 \)) and CVD (Coef. = -0.179, 95% CI [-0.308, -0.050], \( P = 0.007 \)) were still significant predictors for IL-6 level, but not sputum neutrophil counts (Coef. = -0.0003, 95% CI [-0.002, 0.002], \( P = 0.745 \)).

**DISCUSSION**

This study assessed systemic inflammation in patients with obstructive airway diseases including asthma, COPD and asthma-COPD overlap syndrome and healthy controls. Our data shows that systemic inflammation is frequently present in asthma-COPD overlap syndrome, with a similar prevalence to COPD, where it is present in between 47.6% and 81.0% of patients. In asthma-COPD overlap syndrome, elevated IL-6 was common, and after adjusting for confounding factors, systemic levels of IL-6 was strongly associated with FEV1% predicted and cardiovascular disease. Multivariate logistic regression modeling suggests that age, CCI and IL-6 level were associated with asthma-COPD overlap syndrome.

Asthma-COPD overlap syndrome is common in patients with obstructive airway disease, particularly in older people, and its prevalence continues to increase with age.\(^{16,17}\) In this study, there were 53.2% of subjects with an overlapping pattern of airflow obstruction. These data support the high prevalence of asthma-COPD overlap syndrome reported in the study by Marsh et al., in which 55% of COPD patients present an asthma predominant phenotype.\(^{18}\) In the majority of previous reports of systemic inflammation in chronic airway disease, patients with asthma-COPD overlap syndrome were either not properly defined,\(^{19-21}\) or were specifically excluded, this may result in mixed study population of patients with (A) fixed airflow obstruction and, (B) both airflow reversibility and fixed obstruction, which may represent different disease pathogenesis. Furthermore, smoking history was used as an exclusion criterion and as a result a great number of patients were excluded from the studies.\(^{19-22}\) It is well known that studies, in particular randomised controlled trials (RCTs), in asthma and COPD are based on highly selected subgroups of people, however this does not reflect the spectrum of patient seen in practice\(^{23,24}\) leading to evidence gaps. Real world studies such as ours that have examined a wide spectrum of obstructive airway disease patients and specially include and analyse the asthma-COPD overlap phenotype are needed in order to inform practice.
Therefore, this study provides novel data in relation to this patient population.

We have addressed the prevalence and role of systemic inflammation in asthma-COPD overlap syndrome, an observation that has received little attention elsewhere. CRP is an acute phase protein present in various pathological conditions, and is frequently used as a surrogate marker for inflammation. IL-6 is a pro-inflammatory cytokine and is the primary hepatocyte stimulating factor for acute phase proteins. We choose to determine the two inflammatory markers because both have been commonly studied in COPD and in some asthma studies. Our data shows that patients with asthma-COPD overlap syndrome had significantly higher IL-6 levels, and there were a greater proportion of patients in this group with elevated IL-6 levels compared to the asthma group, however, levels of systemic inflammation mediators did not differ between COPD and asthma-COPD overlap syndrome. Thus, the common presence of systemic inflammation seen in asthma-COPD overlap syndrome, together with the similar levels of systemic inflammatory mediators with the COPD group, suggest that this group resembles COPD in terms of systemic inflammation.

Elevated levels of systemic inflammatory mediators are attributed to multiple factors, such as aging, cigarette smoking, obesity, cardiovascular diseases, other co-morbidities and statin use. We used multivariate linear regression analysis in order to control for the effects of these confounders on levels of systemic inflammatory mediators. After adjustment, BMI was independently associated with CRP level. CRP levels were associated with FEV1% predicted in single linear regression, however when adjusted for other confounders, the association was no longer significant, suggesting that CRP may not be a major marker of airflow obstruction. This differs from some other studies, perhaps because of different populations studied, and limited confounders adjusted for in those studies. The present study examined a wide range of potential confounders for the frequently reported inflammatory mediators CRP and IL-6, which led to different associations being identified; we therefore argue that this approach is rational and pivotal in the assessment of systemic inflammation.

Our data show that after controlling for other confounders, FEV1% predicted was significantly and inversely correlated with IL-6 level. Walter et al. found that serum IL-6 is inversely related to FEV1 independent of age and smoking, and high levels of IL-6 were associated with increased risk of developing COPD. The population-based Burden of Obstructive Lung Disease study suggests that IL-6 was independently related to lower FEV1 and FVC value, and was associated with a faster FEV1% predicted decline in COPD. Interestingly, an earlier study has shown that Oncostatin M, a member of IL-6 family of cytokines, was associated with incompletely reversible airflow obstruction in asthma via modulating airway inflammation. In our study the elevation of IL-6 level was seen in the asthma-COPD overlap syndrome group but not in the ‘pure asthma’ group compared to healthy controls, it is possible that the elevation of IL-6 level is associated with an fixed airflow obstruction in asthma, i.e. an overlap pattern, rather than as an universal increase in all the asthmatics, and this requires further study.

We did not find a difference in IL-6 levels between those with asthma and healthy controls, these data support the results of an early study but conflict with some other studies. The reason of this is unclear but may due to small number of the patients in the asthma group in our study. Moreover, the patient population and also the healthy controls in this study were older than those recruited in previous studies. Finally, we used strict physiological criteria to define each group and the patients in the asthma group had AHR or BDR without a coexisting of airflow obstruction. In previous studies, patients with fixed airflow obstruction were not excluded from the asthma population. This results in a mixed study population with asthma and overlap syndrome in their ‘asthma group’, and may contribute to the elevation of IL-6 level compared to healthy controls seen in those studies.

In the logistic regression model of asthma-COPD overlap syndrome, age, CCI and IL-6 level were significantly associated with this specific phenotype. Relatively early onset of asthma symptoms and long-term airway inflammation and remodeling may lead to an irreversible airflow obstruction in asthma-COPD overlap syndrome with younger age being identified in this study. After controlling for other factors, an elevation of IL-6 was also significantly associated with the overlap syndrome, indicating a pivotal role of IL-6 in asthma-COPD overlap syndrome. Additionally, higher levels of IL-6 in patients with CVD compared to those without CVD, together with the inverse correlation between the IL-6 level and FEV1% predicted, may indicate that IL-6 is a potentially important systemic inflammatory mediator that is involved in the lung function impairment and comorbidities in obstructive airway disease.

There are some limitations of this study. We observed a relatively small number of patients for the asthma group. Asthma is a potential risk factor for developing COPD, and persistent airway inflammation and the subsequent airway remodeling in asthma may result in an incompletely reversible airflow obstruction in older asthmatics. Since this may represent the natural history of asthma physiologically, identifying fewer patients as ‘pure asthma’ in this older population is not unexpected. Additionally, the consistency of the proportion of patients that had asthma-COPD overlap syndrome with previously published studies indicates the proportion of the patients in each group is not likely due to an intentional selection. The application of the strict physiological criteria to define the disease subgroups may also contributed to the small sample size, in the asthma group particularly. Future studies with a larger sample size are required to confirm the research findings. We measured two of the typical mediators to assess systemic inflammation, in

http://e-aair.org

Allergy Asthma Immunol Res. 2014 July;6(4):316-324. http://dx.doi.org/10.4168/aair.2014.6.4.316
future studies measurement a panel of biomarkers is suggested. Moreover, to investigate the predictors for developing asthma-COPD overlap syndrome and prognostic role of systemic inflammation in OAD, a longitudinal study will be valuable.

At present there is no agreed definition for the diagnosis of asthma-COPD overlap syndrome. Other definitions have been proposed based on the presence of specific airway inflammatory pattern, but these inflammatory phenotypes are not specific for asthma and COPD such as airway eosinophilia was present only in 48% of asthmatics, while 34% of patients with COPD had an eosinophilic inflammation. We used the physiological lung function criteria with the presence where possible of AHR. Most patients in asthma-COPD overlap syndrome group (92.7%) showed bronchial reactivity to hypertonic saline, which is an indirect bronchial provocation agent with greater specificity for asthma, and is less susceptible to the effects of baseline airflow obstruction compared to direct acting agents (e.g. methacholine). It also had the advantage of permitting collection of induced sputum. In patients whose lung function was too low to undergo a hypertonic saline challenge we used the presence of BDR in the definition of asthma-COPD overlap syndrome. In the absence of better diagnostic criteria, we urge that this is justified as the overlap group had clinical symptoms and physiological changes of asthma and COPD. Additionally, the concordance with the proportion of patients that had asthma-COPD overlap syndrome with other studies may also indicate the rationality of this definition. Validation of the definition is required to promote a consensus in the respiratory community.

In conclusion, our data identified a high prevalence of systemic inflammation in older people with the asthma-COPD overlap syndrome. Patients with asthma-COPD overlap syndrome resembled COPD in terms of systemic inflammation. Age, CCI and serum IL-6 level were independently associated with asthma-COPD overlap syndrome. Elevated IL-6 was significantly elevated in asthma-COPD overlap syndrome compared with healthy controls and asthma, and was independently associated with the degree of lung function impairment and cardiovascular disease, therefore might be an important inflammatory biomarker that is associated with airflow obstruction and the systemic effects observed. Further research on systemic inflammation in this population would improve our understanding and provide potential treatment targets for older people with obstructive airway disease.

ACKNOWLEDGMENTS

We acknowledge the technical support from Kelly Steel, Calida Garside, Erin Harvey, Kevin Oreo and Michelle Gleeson. This work was financially supported by the National Health and Medical Research Council, and the National Health and Medical Research Council Centre for Respiratory and Sleep Medicine, the Co-operative Research Centre (CRC) for Asthma and Airways, Australia. The financial sponsors played no role in the design, execution, analysis and interpretation of data or writing of the study.

REFERENCES

1. Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax 2009;64:278-35.
2. Hardin M, Silverman EK, Barr RG, Hansel NN, Schroeder JD, Make BJ, Crapo JD, Hersh CP; COPDGene Investigators. The clinical features of the overlap between COPD and asthma. Respir Res 2011;12:127.
3. De Martinis M, Franceschi C, Monti D, Ginaldi L. Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity. FEBS Lett 2005;579:2033-9.
4. Wood LG, Baines KJ, Fu J, Scott HA, Gibson PG. The neutrophilic inflammatory phenotype is associated with systemic inflammation in asthma. Chest 2012;142:86-93.
5. Dickens JA, Miller BE, Edwards LD, Silverman EK, Lomas DA, Tal-Singer R; Evaluation of COPD Longitudinally to Identify Surrogate Endpoints (ECLIPSE) study investigators. COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir Res 2011;12:146.
6. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjærg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:250-5.
7. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumbley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387-97.
8. Bastard JP, Maach M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006;17:4-12.
9. Gibson PG, McDonald VM, Marks GB. Asthma in older adults. Lancet 2010;376:803-13.
10. McDonald VM, Simpson JL, Higgins I, Gibson PG. Multidimensional assessment of older people with asthma and COPD: clinical management and health status. Age Ageing 2011;40:42-9.
11. Dreborg S. Bronchial hyper-reactivity and skin sensitivity. Clin Exp Allergy 1991;21:529.
12. Gibson PG, Wlodarczyk JW, Hensley MJ, Gleeson M, Henry RL, Cripps AW, Clancy RL; Epidemiological association of airway inflammation with asthma symptoms and airway hyperresponsiveness in childhood. Am J Respir Crit Care Med 1998;158:36-41.
13. Jones PW, Quirk FH, Baveystock CM, Littlejohns P; self-complete measure of health status for chronic airflow limitation. The St. George’s Respiratory Questionnaire. Am Rev Respir Dis 1992;145:1321-7.
14. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
15. Knudson RJ, Slatin RC, Lebowitz MD, Burrows B. The maximal expiratory flow-volume curve. Normal standards, variability, and effects of age. Am Rev Respir Dis 1976;113:587-600.
16. Zeki AA, Schivo M, Chan A, Albertson TE, Louie S. The asthma-COPD overlap syndrome: a common clinical problem in the elder-
ly. J Allergy (Cairo) 2011;2011:861926.

17. McDonald VM, Higgins I, Gibson PG. Managing older patients with coexistent asthma and chronic obstructive pulmonary disease: diagnosti- 
cographic and therapeutic challenges. Drugs Aging 2013;30:1-17.

18. Marsh SE, Travers J, Weatherall M, Williams MV, Aldington S, Shirt-
cliffe PM, Hansell AL, Nowitz MR, McNaughton AA, Soriano JB, 
Beasley RW. Proportional classifications of COPD phenotypes. 
Thorax 2008;63:761-7.

19. Higashimoto Y, Yamagata Y, Taya S, Iwata T, Okada M, Ishiguchi T, 
Sato H, Itoh H. Systemic inflammation in chronic obstructive pul-
monary disease and asthma: similarities and differences. Respiro-
logy 2008;13:128-33.

20. Eagan TM, Ueland T, Wagner PD, Hardie JA, Molnæs TE, Damås 
JK, Aukrust P, Bakke PS. Systemic inflammatory markers in COPD: 
results from the Bergen COPD Cohort Study. Eur Respir J 2010; 
35:540-8.

21. Singh D, Edwards L, Tal-Singer R, Rennard S. Sputum neutrophils 
as a biomarker in COPD: findings from the ECLIPSE study. Resp 
Res 2010;11:77.

22. Wu TL, Chang PY, Tsao KC, Sun CF, Wu LL, Wu JT. A panel of multi-
ple markers associated with chronic systemic inflammation and 
the risk of atherogenesis is detectable in asthma and chronic ob-
structive pulmonary disease. J Clin Lab Anal 2007;21:367-71.

23. Travers J, Marsh S, Williams M, Weatherall M, Caldwell B, Shirt-
cliffe P, Aldington S, Beasley R. External validity of randomised 
controlled trials in asthma: to whom do the results of the trials ap-
ply? Thorax 2007;62:219-23.

24. Travers J, Marsh S, Caldwell B, Williams M, Aldington S, Weatherall 
M, Shirtcliffe P, Beasley R. External validity of randomized con-
trolled trials in COPD. Respir Med 2007;101:1313-20.

25. Kashur I, Zewnicki D, Samols D. What does minor elevation of 
C-reactive protein signify? Am J Med 2006;119:166.e17-28.

26. Heinrich PC, Horn F, Graeve L, Dittrich E, Kerr I, Müller-Newen G, 
Heinrich PC, Horn F, Graeve L, Dittrich E, Kerr I, Müller-Newen G, 
Grötzinger J, Wollmer A. Interleukin-6 and related cytokines: effect 
on the acute phase reaction. Z Ernahrungswiss 1998;37 Suppl 1:43-9.

27. Takemura M, Matsumoto H, Niiim A, Ueda T, Matsuoka H, Yama-
doctoral trials in COPD. Respir Med 2005;99:1568-72.

28. Pinto-Plata VM, Müllerova H, Toso JF, Feudjo-Tepie M, Soriano JB, 
Takemura M, Matsumoto H, Niiim A, Ueda T, Matsuoka H, Yama-
doctoral trials in COPD. Respir Med 2007;101:1313-20.

29. Genest J. C-reactive protein: risk factor, biomarker and/or therapeu-
tic target? Can J Cardiol 2010;26 Suppl A:41A-44A.

30. Thorleifsson SJ, Margretardottir OB, Gudmundsson G, Olafsson J, 
Benediktsdottir B, Ústur AS, Gislason T. Chronic airflow 
obstruction and markers of systemic inflammation: results from the 
BOLD study in Iceland. Respir Med 2009;103:1548-53.

31. Walter RE, Wilk JB, Larson MG, Vasas RN, Keaney JF Jr, Lipinska 
I, O’Connor GT, Benjamin EJ. Systemic inflammation and COPD: the 
Framingham Heart Study. Chest 2008;133:19-25.

32. Yanbaeva DG, Dentener MA, Spruit MA, Hoving-Duistermaat JJ, 
Kotz D, Passos VL, Wouters EF. IL6 and CRP haplotypes are associ-
ated with COPD risk and systemic inflammation: a case-control 
study. BMC Med Genet 2009;10:23.

33. O’Hara KA, Kedda MA, Thompson PJ, Knight DA. Oncostatin M: 
an interleukin-6-like cytokine relevant to airway remodelling and 
the pathogenesis of asthma. Clin Exp Allergy 2003;33:1026-32.

34. Simpson JL, Baines KJ, Boyle MJ, Scott RJ, Gibson PG. Oncostatin 
M (OSM) is increased in asthma with incompletely reversible air-
flow obstruction. Exp Lung Res 2009;35:781-94.

35. Sánchez-Guerrero I, Vegara RP, Herrero N, García-Alonso AM, 
Luna A, Alvarez MR. Cytokine serum profiles in allergic and non-
allergic asthma. Increased production of IL-10 by non-allergic 
asthmatic patients. Allergol Immunopathol (Madr) 1997;25:98-103.

36. Yokoyama A, Kohno N, Fujino S, Hamada H, Ioue Y, Fujikoa S, 
Ishida S, Hivada K. Circulating interleukin-6 levels in patients with 
bronchial asthma. Am J Respir Crit Care Med 1995;151:1354-8.

37. Wong CK, Ho CY, Ko FW, Chan CH, Ho AS, Hui DS, Lam CW. Pro-
inflammatory cytokines (IL-17, IL-6, IL-18 and IL-2) and Th cyto-
kines (IFN-gamma, IL-4, IL-10 and IL-13) in patients with allergic 
asthma. Clin Exp Immunol 2001;125:177-83.

38. ten Brinke A. Risk factors associated with irreversible airflow limi-
tation in asthma. Curr Opin Allergy Clin Immunol 2008;8:63-9.

39. Soriano JB, Davis KJ, Coleman B, Visick G, Mannino D, Pride NB. 
The proportional Venn diagram of obstructive lung disease: two 
approximations from the United States and the United Kingdom. 
Chest 2003;124:74-81.

40. Agustí A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller 
BE, Vestbo J, Lomas DA, Calverley PM, Wouters E, Crim C, Yates 
JC, Silverman EK, Coxson HO, Bakke P, Mayer RJ, Celli B; Evalua-
tion of COPD Longitudinally to Identify Predictive Surrogate End-
points (ECLIPSE) Investigators. Persistent systemic inflammation is 
associated with poor clinical outcomes in COPD: a novel phenoe-
type. PLoS One 2012;7:e37483.

41. Soler-Cataluña JJ, Costó B, Izquierdo JL, López-Campos JL, Marín 
JM, Agüero R, Balauria A, Carrizaro S, Esteban C, Galdiz JB, González 
MC, Miravitlles M, Monsé E, Montemayor T, Morera J, Ortega F, 
Peces-Barba G, Puente L, Rodríguez JM, Sala E, Sauleda I, Soriano 
JB, Viejo JL. Consensus document on the overlap phenotype 
(COPD-asthma in COPD. Arch Bronconeumol 2012;48:331-7.

42. Bafadhel M, McCormick M, Saha S, McKenna S, Shelley M, Harga-
don B, Mistry V, Reid C, Parker D, Dodson P, Jenkins M, Lloyd A, 
Rugman P, Newbold P, Brightling CE. Profiling of sputum inflam-
matory mediators in chronic and obstructive pulmonary disease. 
Respiration 2012;83:36-44.

43. Joos GF, O’Connor B, Anderson SD, Chung F, Cockcroft DW, 
Dhahén B, DImparri G, Foresi A, Hargreave FE, Holgate ST, Inman 
D, Lötvall J, Magnussen H, Polosa R, Postma DS, Riedler J; ERS 
Task Force. Indirect airway challenges. Eur Respir J 2003;21:1050-68.

44. Cockcroft D, Davis B. Direct and indirect challenges in the clinical as-
sessment of asthma. Ann Allergy Asthma Immunol 2009;103:363-70.

45. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, 
Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Peder-
son OF, Wanger J. Interpretative strategies for lung function tests. 
Respir Med 2005;99:468-81.